acetylcarnitine has been researched along with Disease Exacerbation in 5 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS)." | 5.17 | Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. ( Beghi, E; Bella, VL; Bonito, V; Buzzi, P; Caponnetto, C; Chiò, A; Corbo, M; Giannini, F; Inghilleri, M; Logroscino, G; Lorusso, L; Lunetta, C; Mazzini, L; Messina, P; Mora, G; Perini, M; Pupillo, E; Quadrelli, ML; Silani, V; Simone, IL; Tremolizzo, L, 2013) |
| "ALC slows the progression of Alzheimer's disease in younger subjects, and the use of the trilinear approach to estimate the average rate of change may prove valuable in pharmacological trials." | 2.69 | Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. ( Bravi, D; Brooks, JO; Carta, A; Yesavage, JA, 1998) |
| " While earlier no treatment was available, in the recent decade an antioxidant therapy became very popular using combinations of high dosage antioxidant vitamins C, E, beta carotene and zinc." | 2.44 | [Metabolic therapy for early treatment of age-related macular degeneration]. ( Corrado Balacco, G; Fehér, J; Kovács, B; Kovács, I; Schvöller, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, DQ | 1 |
| Cao, G | 1 |
| Chen, H | 1 |
| Argyopoulos, CP | 1 |
| Yu, H | 1 |
| Su, W | 1 |
| Chen, L | 1 |
| Samuels, DC | 1 |
| Zhuang, S | 1 |
| Bayliss, GP | 1 |
| Zhao, S | 1 |
| Yu, XY | 1 |
| Vaziri, ND | 1 |
| Wang, M | 1 |
| Liu, D | 1 |
| Mao, JR | 1 |
| Ma, SX | 1 |
| Zhao, J | 1 |
| Zhang, Y | 1 |
| Shang, YQ | 1 |
| Kang, H | 1 |
| Ye, F | 1 |
| Cheng, XH | 1 |
| Li, XR | 1 |
| Zhang, L | 1 |
| Meng, MX | 1 |
| Guo, Y | 1 |
| Zhao, YY | 1 |
| Beghi, E | 1 |
| Pupillo, E | 1 |
| Bonito, V | 1 |
| Buzzi, P | 1 |
| Caponnetto, C | 1 |
| Chiò, A | 1 |
| Corbo, M | 1 |
| Giannini, F | 1 |
| Inghilleri, M | 1 |
| Bella, VL | 1 |
| Logroscino, G | 1 |
| Lorusso, L | 1 |
| Lunetta, C | 1 |
| Mazzini, L | 1 |
| Messina, P | 1 |
| Mora, G | 1 |
| Perini, M | 1 |
| Quadrelli, ML | 1 |
| Silani, V | 1 |
| Simone, IL | 1 |
| Tremolizzo, L | 1 |
| Wadman, RI | 1 |
| Bosboom, WM | 1 |
| van der Pol, WL | 1 |
| van den Berg, LH | 1 |
| Wokke, JH | 1 |
| Iannaccone, ST | 1 |
| Vrancken, AF | 1 |
| Fehér, J | 1 |
| Kovács, B | 1 |
| Kovács, I | 1 |
| Schvöller, M | 1 |
| Corrado Balacco, G | 1 |
| Brooks, JO | 1 |
| Yesavage, JA | 1 |
| Carta, A | 1 |
| Bravi, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| A Patient Centric Motor Neuron Disease Activities of Daily Living Scale[NCT02852278] | 410 participants (Actual) | Observational | 2016-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for acetylcarnitine and Disease Exacerbation
| Article | Year |
|---|---|
Drug treatment for spinal muscular atrophy types II and III.
Topics: Acetylcarnitine; Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids; | 2012 |
[Metabolic therapy for early treatment of age-related macular degeneration].
Topics: Acetylcarnitine; Adenosine Triphosphate; Antioxidants; Ascorbic Acid; beta Carotene; Coenzymes; Dise | 2007 |
2 trials available for acetylcarnitine and Disease Exacerbation
| Article | Year |
|---|---|
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.
Topics: Acetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Metho | 2013 |
Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach.
Topics: Acetylcarnitine; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Disea | 1998 |
1 other study available for acetylcarnitine and Disease Exacerbation
| Article | Year |
|---|---|
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.
Topics: Acetylcarnitine; Animals; Canavanine; Carnitine; Case-Control Studies; Disease Models, Animal; Disea | 2019 |